What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The clinical trial evidence from KEYNOTE-407 demonstrates that pembrolizumab combination therapy significantly improves overall survival compared to standard chemotherapy, with a median overall survival of 17.2 months versus 11.6 months for standard care. This indicates a clear clinical advantage, particularly for patients with PD-L1 scores of 1% to 49%. However, the results for patients with PD-L1 scores of less than 1% and 50% or more are less certain, which prevents a higher rating.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for pembrolizumab combination therapy are within NICE’s acceptable range for both PD-L1 subgroups, with an ICER below £50,000 per QALY gained. This indicates that the therapy is clearly cost-effective under common thresholds, despite some uncertainties in the estimates for the urgent intervention subgroup.
Is there quality-of-life evidence payers weigh? — Quality of life
While specific HRQoL data is not extensively detailed, the committee acknowledges that pembrolizumab combination therapy is likely to improve quality of life for patients with untreated metastatic squamous NSCLC, particularly given the poor prognosis associated with this condition. The treatment’s potential to extend life and improve symptoms suggests moderate gains in HRQoL.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The safety profile of pembrolizumab combination therapy is acceptable, with no new safety data presented that would raise significant concerns. The committee noted that the adverse events associated with the therapy are manageable and comparable to existing treatments, indicating a good safety profile.
Was the drug compared against what payers expect? — Comparator Selection
The treatment was compared against appropriate standard-of-care alternatives, specifically standard chemotherapy regimens. The committee recognized that the indirect treatment comparison was relevant and aligned with clinical practice, supporting the robustness of the evidence.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population is moderately representative of the intended patient population, with subgroup analyses based on PD-L1 status. However, there are some limitations in the representation of patients with PD-L1 scores of less than 1%, which affects the generalizability of the findings.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Pembrolizumab combination therapy can be integrated into existing care pathways with minor adjustments. The treatment aligns with current clinical practices for managing metastatic squamous NSCLC, requiring only slight modifications to existing protocols.
Are the wider system costs understood? — Resource Use and Cost Implications
The budget impact of pembrolizumab combination therapy is manageable, with the potential for cost savings due to its effectiveness. The committee noted that the therapy is likely to be resource-efficient, particularly for the PD-L1 subgroup with scores of 0% to 49%.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is strong, primarily derived from the KEYNOTE-407 trial, which is a well-designed RCT. However, there are some methodological concerns regarding the generalizability of the results to clinical practice, particularly for certain PD-L1 subgroups.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are uncertainties regarding the cost-effectiveness estimates, particularly for the urgent intervention subgroup, the overall context supports the use of pembrolizumab combination therapy. The committee acknowledged the unmet need for effective treatments in this population, which mitigates some of the uncertainties.
